JP2015505319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505319A5 JP2015505319A5 JP2014551643A JP2014551643A JP2015505319A5 JP 2015505319 A5 JP2015505319 A5 JP 2015505319A5 JP 2014551643 A JP2014551643 A JP 2014551643A JP 2014551643 A JP2014551643 A JP 2014551643A JP 2015505319 A5 JP2015505319 A5 JP 2015505319A5
- Authority
- JP
- Japan
- Prior art keywords
- antigens
- polypeptide
- antibody
- hla
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 48
- 108091007433 antigens Proteins 0.000 claims 48
- 102000036639 antigens Human genes 0.000 claims 48
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 239000012634 fragment Substances 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 15
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 7
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000008685 targeting Effects 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- -1 GD3 ganglioside Chemical class 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102100022749 Aminopeptidase N Human genes 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 2
- 102000011899 Aquaporin 2 Human genes 0.000 claims 2
- 108010036221 Aquaporin 2 Proteins 0.000 claims 2
- 241000282836 Camelus dromedarius Species 0.000 claims 2
- 241000251730 Chondrichthyes Species 0.000 claims 2
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 108010059045 HLA-C*06 antigen Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 241000282842 Lama glama Species 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 102100040120 Prominin-1 Human genes 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000006471 dimerization reaction Methods 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 102100035716 Glycophorin-A Human genes 0.000 claims 1
- 108091005250 Glycophorins Proteins 0.000 claims 1
- 108010089211 HLA-A*25 antigen Proteins 0.000 claims 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims 1
- 108010004141 HLA-B35 Antigen Proteins 0.000 claims 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 claims 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims 1
- 108010039075 HLA-B8 Antigen Proteins 0.000 claims 1
- 108010070768 HLA-C*03 antigen Proteins 0.000 claims 1
- 108010069149 HLA-C*04 antigen Proteins 0.000 claims 1
- 108010007655 HLA-C*70 antigen Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 claims 1
- 102000004874 Synaptophysin Human genes 0.000 claims 1
- 108090001076 Synaptophysin Proteins 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 206010054000 Type II hypersensitivity Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 102000004111 amphiphysin Human genes 0.000 claims 1
- 108090000686 amphiphysin Proteins 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000008026 type II hypersensitivity Effects 0.000 claims 1
- 230000024161 type IIb hypersensitivity Effects 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12151125 | 2012-01-13 | ||
| EP12151125.7 | 2012-01-13 | ||
| PCT/EP2013/050603 WO2013104804A2 (en) | 2012-01-13 | 2013-01-14 | Dual antigen-induced bipartite functional complementation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505319A JP2015505319A (ja) | 2015-02-19 |
| JP2015505319A5 true JP2015505319A5 (enExample) | 2016-03-03 |
| JP6408915B2 JP6408915B2 (ja) | 2018-10-17 |
Family
ID=47715984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551643A Active JP6408915B2 (ja) | 2012-01-13 | 2013-01-14 | 二重抗原誘導型の二部分機能相補 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20150079093A1 (enExample) |
| EP (3) | EP3333190A1 (enExample) |
| JP (1) | JP6408915B2 (enExample) |
| KR (2) | KR102100817B1 (enExample) |
| CN (2) | CN108034006A (enExample) |
| AU (1) | AU2013208895B2 (enExample) |
| CA (1) | CA2861003C (enExample) |
| CY (1) | CY1119928T1 (enExample) |
| DK (1) | DK2802607T3 (enExample) |
| EA (1) | EA033947B1 (enExample) |
| ES (1) | ES2653287T3 (enExample) |
| HR (1) | HRP20171912T1 (enExample) |
| HU (1) | HUE035207T2 (enExample) |
| IL (1) | IL233566B (enExample) |
| LT (1) | LT2802607T (enExample) |
| MX (1) | MX359411B (enExample) |
| NO (1) | NO2802607T3 (enExample) |
| PL (1) | PL2802607T3 (enExample) |
| PT (1) | PT2802607T (enExample) |
| RS (1) | RS56773B1 (enExample) |
| SG (1) | SG11201403997SA (enExample) |
| SI (1) | SI2802607T1 (enExample) |
| WO (1) | WO2013104804A2 (enExample) |
| ZA (1) | ZA201405658B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG194510A1 (en) | 2011-04-22 | 2013-12-30 | Emergent Product Dev Seattle | Prostate-specific membrane antigen binding proteins and related compositionsand methods |
| DK2914286T3 (da) | 2012-10-30 | 2021-11-08 | Aravax Pty Ltd | Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf |
| KR20160075532A (ko) | 2013-09-25 | 2016-06-29 | 아라백스 피티와이 엘티디 | 신규한 면역치료제 조성물 및 이의 용도 |
| CA2946289C (en) * | 2014-03-25 | 2018-08-07 | Five3 Genomics, Llc | Systems and methods for rna analysis in functional confirmation of cancer mutations |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| EP3212232A4 (en) * | 2014-10-31 | 2019-01-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TETRAVALENT TLR9 BISPECIFIC ANTIBODIES |
| CN104592391B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| BR112017020058A2 (pt) * | 2015-03-20 | 2018-06-05 | Childrens Nat Medical Ct | processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células. |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| EP3112375A1 (en) * | 2015-07-03 | 2017-01-04 | Ludwig-Maximilians-Universität München | Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| MX387275B (es) | 2015-10-12 | 2025-03-18 | Nantomics Llc | Neoepítopos virales y sus usos |
| AU2016358296B2 (en) * | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| AU2017214692B2 (en) | 2016-02-06 | 2021-11-04 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2017189751A1 (en) | 2016-04-26 | 2017-11-02 | The University Of Utah Research Foundation | Target-binding activated split reporter systems for analyte detection and related components and methods |
| BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| CN109641046B (zh) | 2016-05-20 | 2023-11-07 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN105920618A (zh) * | 2016-06-13 | 2016-09-07 | 上海交通大学医学院附属新华医院 | 一种生物靶向纳米基因材料及其制造方法 |
| EP3714944A1 (en) | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| EP3263595A1 (en) | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| CN108085333B (zh) * | 2016-11-14 | 2021-06-29 | 中国科学院分子植物科学卓越创新中心 | 一种延缓薯类植物生理性变质的方法 |
| JP6812551B2 (ja) | 2016-11-23 | 2021-01-13 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原結合タンパク質 |
| JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 |
| WO2018136725A1 (en) * | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Innate immune cell inducible binding proteins and methods of use |
| TW201834688A (zh) | 2017-02-24 | 2018-10-01 | 日商中外製藥股份有限公司 | 藥學組成物、抗原結合分子、治療方法以及篩選方法 |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| JP7618192B2 (ja) * | 2017-03-28 | 2025-01-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 移植された組織を拒絶反応から保護するための方法 |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| MX2020002667A (es) | 2017-09-08 | 2020-08-03 | Maverick Therapeutics Inc | Proteinas de unión condicionalmente activadas restringidas. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
| WO2019122350A1 (en) | 2017-12-21 | 2019-06-27 | Gernot Stuhler | Specific dosage regimen for hemibody therapy |
| JP7368453B2 (ja) | 2018-05-03 | 2023-10-24 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質 |
| WO2019222283A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| CA3104185A1 (en) * | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Antibody tumor-targeting assembly complexes |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| AU2019402097A1 (en) * | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| CN120484127A (zh) | 2019-03-05 | 2025-08-15 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| CA3138854A1 (en) | 2019-05-02 | 2020-11-05 | The General Hospital Corporation | Teac and attac immunooncology compositions and methods |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| JP7737996B2 (ja) * | 2020-01-23 | 2025-09-11 | エクスマ バイオテック コーポレイション | Ｈｅｒ２に対するキメラ抗原受容体およびその使用方法 |
| CN114945596A (zh) * | 2020-01-29 | 2022-08-26 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
| IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| PE20230434A1 (es) * | 2020-07-10 | 2023-03-08 | Hoffmann La Roche | Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas |
| AU2021350342A1 (en) | 2020-09-24 | 2023-03-09 | Morphosys Ag | Novel human antibodies binding to human CD3 epsilon |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| MX2023008084A (es) * | 2021-01-12 | 2023-07-13 | Hoffmann La Roche | Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas. |
| CN112724236B (zh) * | 2021-01-15 | 2022-03-04 | 武汉大学 | 一种两性蛋白1的抗原肽及其抗体与应用 |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| AU2022281108A1 (en) * | 2021-05-28 | 2023-12-14 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
| CN117715939A (zh) | 2021-07-27 | 2024-03-15 | 莫佛塞斯公司 | 抗原结合分子的组合 |
| CN113846115B (zh) * | 2021-09-24 | 2023-10-17 | 广州医科大学 | 一种屋尘螨I类变应原pro-Der p 1重组蛋白及其制备方法与应用 |
| EP4490197A2 (en) | 2022-03-24 | 2025-01-15 | Actinium Pharmaceuticals, Inc. | Humanized anti-cd45 antibodies |
| CN114773452A (zh) * | 2022-04-21 | 2022-07-22 | 谭宏凯 | 牛乳乳清主要过敏原α-乳白蛋白的IgE结合表位 |
| EP4562172A2 (en) * | 2022-07-25 | 2025-06-04 | Vironexis Biotherapeutics Inc. | Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis |
| CN117305248A (zh) * | 2022-09-09 | 2023-12-29 | 复星凯特生物科技有限公司 | 抗EGFR和cMet双特异性嵌合抗原受体及其应用 |
| EP4619427A1 (en) * | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Recombinant binding proteins with activatable effector domain |
| JP2025539760A (ja) | 2022-11-15 | 2025-12-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合分子 |
| EP4378529A1 (en) * | 2022-12-03 | 2024-06-05 | Universitätsklinikum Hamburg-Eppendorf | Antibody for use in a therapy involving effector cell engagement |
| CN120917044A (zh) * | 2023-04-03 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 激动性拆分型抗体 |
| CN120882744A (zh) * | 2023-04-03 | 2025-10-31 | 豪夫迈·罗氏有限公司 | 一体化激动性抗体 |
| WO2024241205A1 (en) * | 2023-05-19 | 2024-11-28 | Seoul National University R&Db Foundation | Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors |
| WO2025003511A1 (en) | 2023-06-30 | 2025-01-02 | Morphosys Ag | Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025016902A1 (en) * | 2023-07-14 | 2025-01-23 | Julius-Maximilians-Universität Würzburg | Multivalent single-partite antibodies for dual-antigen restricted immunotherapy |
| WO2025036892A1 (en) | 2023-08-14 | 2025-02-20 | Morphosys Ag | Cycat halfbody molecules comprising sterically occluding moieties |
| WO2025082777A1 (en) | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025237931A1 (en) | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| WO1993015210A1 (en) * | 1992-01-23 | 1993-08-05 | Merck Patent Gmbh | Monomeric and dimeric antibody-fragment fusion proteins |
| GB9221657D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| ES2401428T3 (es) * | 2002-04-10 | 2013-04-19 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
| AU2003266502A1 (en) | 2002-08-16 | 2004-03-03 | The University Of Tokyo | Method of assaying interaction between proteins |
| JPWO2004033499A1 (ja) * | 2002-10-11 | 2006-02-09 | 中外製薬株式会社 | 細胞死誘導剤 |
| CA2505515C (en) * | 2002-11-07 | 2013-08-27 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
| KR101229731B1 (ko) * | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| US7901680B2 (en) * | 2005-10-19 | 2011-03-08 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
| GB0421836D0 (en) * | 2004-10-01 | 2004-11-03 | Avidex Ltd | T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents |
| JP5102772B2 (ja) * | 2005-11-29 | 2012-12-19 | ザ・ユニバーシティ・オブ・シドニー | デミボディ：二量体化活性化治療剤 |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| GB0919751D0 (en) * | 2009-11-11 | 2009-12-30 | King S College Hospital Nhs Fo | Conjugate molecule |
| CN110066339A (zh) * | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
-
2013
- 2013-01-14 US US14/371,910 patent/US20150079093A1/en not_active Abandoned
- 2013-01-14 SG SG11201403997SA patent/SG11201403997SA/en unknown
- 2013-01-14 RS RS20171357A patent/RS56773B1/sr unknown
- 2013-01-14 EP EP17193746.9A patent/EP3333190A1/en not_active Ceased
- 2013-01-14 KR KR1020147022652A patent/KR102100817B1/ko active Active
- 2013-01-14 CN CN201711383463.0A patent/CN108034006A/zh active Pending
- 2013-01-14 CA CA2861003A patent/CA2861003C/en active Active
- 2013-01-14 HU HUE13704369A patent/HUE035207T2/en unknown
- 2013-01-14 EA EA201400811A patent/EA033947B1/ru not_active IP Right Cessation
- 2013-01-14 WO PCT/EP2013/050603 patent/WO2013104804A2/en not_active Ceased
- 2013-01-14 JP JP2014551643A patent/JP6408915B2/ja active Active
- 2013-01-14 MX MX2014008468A patent/MX359411B/es active IP Right Grant
- 2013-01-14 PT PT137043691T patent/PT2802607T/pt unknown
- 2013-01-14 ES ES13704369.1T patent/ES2653287T3/es active Active
- 2013-01-14 NO NO13704369A patent/NO2802607T3/no unknown
- 2013-01-14 EP EP21174675.5A patent/EP3907241A1/en active Pending
- 2013-01-14 KR KR1020207009766A patent/KR20200040893A/ko not_active Ceased
- 2013-01-14 LT LTEP13704369.1T patent/LT2802607T/lt unknown
- 2013-01-14 CN CN201380012188.5A patent/CN104159923B/zh active Active
- 2013-01-14 AU AU2013208895A patent/AU2013208895B2/en active Active
- 2013-01-14 PL PL13704369T patent/PL2802607T3/pl unknown
- 2013-01-14 HR HRP20171912TT patent/HRP20171912T1/hr unknown
- 2013-01-14 DK DK13704369.1T patent/DK2802607T3/en active
- 2013-01-14 EP EP13704369.1A patent/EP2802607B1/en not_active Revoked
- 2013-01-14 SI SI201330893T patent/SI2802607T1/en unknown
-
2014
- 2014-07-09 IL IL233566A patent/IL233566B/en active IP Right Grant
- 2014-07-30 ZA ZA2014/05658A patent/ZA201405658B/en unknown
-
2017
- 2017-12-21 CY CY20171101342T patent/CY1119928T1/el unknown
-
2019
- 2019-03-01 US US16/289,798 patent/US11427644B2/en active Active
-
2022
- 2022-06-17 US US17/842,915 patent/US20220340681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505319A5 (enExample) | ||
| HRP20171912T1 (hr) | Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom | |
| Rozenbaum et al. | Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia | |
| Dubois et al. | IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56bright NK cells and increases NK-cell cytokine release capabilities | |
| Wei et al. | Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients | |
| MX2020011744A (es) | Molecula de polipeptido con especificidad dual mejorada. | |
| Park et al. | Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients | |
| PH12021552107A1 (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| PH12020500160A1 (en) | Reagents for expanding cells expressing recombinant receptors | |
| JP2018080171A5 (enExample) | ||
| JP2020193210A5 (enExample) | ||
| EP4364809A3 (en) | Cd19 specific chimeric antigen receptor and uses thereof | |
| TR201910814T4 (tr) | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. | |
| MX2021006389A (es) | Anticuerpo cd3 y uso farmaceutico del mismo. | |
| RU2015143207A (ru) | Композиции и способы иммунотерапии | |
| MX2020009475A (es) | Inmunoterapia con celulas car de anticuerpos biespecificos. | |
| JP6466350B2 (ja) | 免疫ロゼットおよび磁性粒子を用いて細胞を分離するための方法 | |
| JP2017014254A5 (enExample) | ||
| MX2019014407A (es) | Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados. | |
| ZA202209069B (en) | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof | |
| MX2022016300A (es) | Anticuerpo anti-trop2. | |
| WO2020223392A3 (en) | Cancer associated antibody compositions and methods of use | |
| Shin et al. | Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46 | |
| WO2020146706A3 (en) | Highly modular biepitopic and bispecific car-t cells for cancer immunotherapy | |
| Dao et al. | Approaching untargetable tumor-associated antigens with antibodies |